Organovo Holdings, Inc. ("Organovo") (Nasdaq: ONVO) announced today that it has terminated the merger agreement with Tarveda Therapeutics, Inc. ("Tarveda"), originally announced on December 16, 2019, and will continue to operate as an independent company. The Company had submitted the merger proposal and other related proposals to be voted upon at a Special Meeting of Stockholders, as described in its definitive proxy materials filed with the Securities and Exchange Commission on February 24, 2020. The Special Meeting of Stockholders was held on March 26, 2020 and adjourned until today. At today’s reconvened special meeting, Organovo’s stockholders did not approve the merger related proposal and Organovo terminated the merger agreement in accordance with its terms.

If you're interested in Organovo Holdings, Inc. (NASDAQ:ONVO), then you might want to consider its beta (a measure of...

Intends to Vote "AGAINST" Proposed Merger With Tarveda Intends to vote “FOR” Reverse Stock Split and Against All Other Provisions  Believes the Board, Which Has Presided Over.

Q2 2018 Organovo Holdings Inc Earnings Call

Organovo Holdings, Inc. ("Organovo") (Nasdaq: ONVO) convened, on March 26, 2020, the special meeting of stockholders (the "Special Meeting") and then adjourned the Special Meeting until Tuesday, April 7, 2020 10:00 A.M. Pacific Time at www.virtualshareholdermeeting.com/ONVO2020 to solicit additional proxies for Organovo Proposals Nos. 1 and 4. Organovo Proposal No. 1 is to approve the issuance of shares of Organovo common stock to the Tarveda Therapeutics, Inc. ("Tarveda") securityholders in the proposed merger and Organovo Proposal No. 4 is to approve the adoption of the Combined Organization 2020 Equity Incentive Plan. These proposals are described in more detail in the proxy statement/prospectus/information statement of Organovo dated February 24, 2020, furnished to Organovo’s stockholders in connection with the solicitation of proxies by the Organovo Board of Directors for use at the Special Meeting. On March 16, 2020, Organovo mailed a notice of change of location to stockholders of record, in compliance with Delaware law, regarding Organovo moving the Special Meeting to a virtual meeting format.

SAN DIEGO, Oct. 02, 2019 -- Organovo Holdings, Inc. (NASDAQ: ONVO) (“Organovo”) today confirmed that it has received a proposal from Viscient Biosciences (“Viscient”), an.

Northwell Health, New York's largest health-care provider, is 3D-printing swabs to help test for the novel coronavirus.

Believes Stockholders Sent a Loud and Clear Message at Special Meeting That They Oppose This Value-Destructive Combination    Encourages Board of Directors to Heed Investor.

Viscient will turn its attention to 3D bioprinting lung tissue for infectivity research to assist global efforts to combat SARS-CoV-2, the novel coronavirus that causes COVID-19.

Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys

Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intends to Vote "AGAINST" Proposed Merger With Tarveda Believes the Board Has a Track Record of Bad Decisions and Poor Business Judgment Since Mid-2017, Including Hiring a CEO.

Organovo Holdings, Inc. ("Organovo") (Nasdaq: ONVO) convened, on March 26, 2020, the special meeting of stockholders and then adjourned the special meeting of stockholders until Tuesday, April 7, 2020 10:00 A.M. Pacific Time at www.virtualshareholdermeeting.com/ONVO2020 to solicit additional proxies for Organovo Proposal Nos. 1 and 4. Organovo Proposal No. 1 is to approve the issuance of shares of Organovo common stock to the Tarveda securityholders in the merger and Organovo Proposal No. 4 is to approve the adoption of the Combined Organization 2020 Equity Incentive Plan.

Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […]

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week lows on Oct. 2) Dova Pharmaceuticals Inc (NASDAQ: DOVA ) Down In The ...

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7) * Dr.Reddy's Laboratories Ltd (NYSE: RDY) * Masimo Corporation (NASDAQ: MASI) * Seattle Genetics, Inc. (NASDAQ: SGEN) * Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 7) * Celcuity Inc (NASDAQ: CELC) * Curis, Inc. (NASDAQ: CRIS) * Helius Medical Technologies Inc (NASDAQ: HSDT) * Menlo Therapeutics Inc (NASDAQ: MNLO) * TherapeuticsMD Inc (NASDAQ: TXMD) * Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)Stocks In Focus COVID-19 Test Sales to Lift GenMark's Q1 Results; Company Raises 2020 Guidance GenMark Diagnostics, Inc (NASDAQ: GNMK) announced preliminary first-quarter results, expecting revenues of about $38.7 million, a 80% year-over-year increase. The company noted that about 80% gross placements included interest in COVID-19 testing SARS-CoV-2 consumable revenues. Analysts, on average, estimate revenues of $24.8 million.The company also raised its full-year revenue guidance from $100-$110 million to $112-$122 million, while the consensus calls for revenues of $108.58 million.The stock climbed 29.56% to $5.83 in after-hours trading.Zomedica Prices Offering of Common Stock, Warrants Zomedica Pharmaceuticals Corp (NYSE: ZOM) said it has priced its previously announced public offering of 33.33 million shares and warrants to purchase up to 1.667 million shares. The company expects gross proceeds of about $4 million from the offering. The offering is expected to close on or about April 9.In after-hours trading, the shares shed 9.95% to 15 cents.Mersana Raises $65M Through At-The-Market Facility Mersana Therapeutics Inc (NASDAQ: MRSN) said it has raised gross proceeds of about $65 million through at-the-market facility with participation based on interest received from Avoro Capital Advisors LLC, Bain Capital Life Sciences, Consonance Capital Investors and David Mott, Mersana's Chairman.The company said it sold about 8.9 million shares at $5.50 per share and 2 million shares at the closing price of $7.74 per share, in each case the market price at the time of sale.Bristol-Myers Squibb Announces Acceptance of U.S. and European Regulatory Submissions for Combo Immunotherapy For Lung Cancer Bristol-Myers Squibb Co (NYSE: BMY) said the U.S. FDA accepted its sBLA for Opdivo-Yervoy combo with a limited course of chemotherapy for the first-line treatment of patients metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations. The European Medicines Agency has also validated a type II variation application for the same combo for the same indication, it added.Acceleron's Hypertension Drug Gets Breakthrough Therapy Designation Acceleron Pharma Inc (NASDAQ: XLRN) said the FDA has granted Breakthrough Therapy Designation to sotatercept for the treatment of patients with pulmonary arterial hypertension.FDA Extends Review Period For Roche's Spinal Muscular Atrophy Drug By 3 Months Roche Holdings AG Basel (OTC: RHHBY) said the FDA has extended the PDUFA date for the review of its NDA for risdiplam by three months to Aug. 24 due to a recent submission of additional data made by Roche, including data from the pivotal SUNFISH Part 2 study.Sage Announces Restructuring, Including Workforce Reduction, to Conserve Cash SAGE Therapeutics Inc (NASDAQ: SAGE) announced a restructuring initiative that would help it to advance its corporate strategy and pipeline. The initiative includes elimination of about 53% of its workforce and a reduction in external expenses, which together is expected to result in annualized savings of about $170 million, of which $150 million is related to SG&A expenses.The company said the workforce reduction will primarily affect Zulresso CIV injection commercial operation and related SG&A support functions.Based on the current operating plan and assumptions, Sage expects its cash position to support operations into 2022.The stock added 1.07% to $29.34 in after-hours trading.Idera Announces Private Placement of Up to $20.7M Worth Common Stock and Warrants Idera Pharmaceuticals Inc (NASDAQ: IDRA) announced an funding agreement for privately placing shares of its common stock together with accompanying warrants to purchase additional shares of common stock in two tranches, with the second tranche to be made at the option of the investor.View more earnings on IBBDepending on the extent to which Tranche 2 is closed, and inclusive of proceeds from the exercise of warrants issuable in this private placement, the company said it will receive up to $20.7 million in gross proceeds.The company said it plans to use the proceeds primarily to fund completion of its ongoing ILLUMINATE-301 trial of its lead product tilsotolimod for the treatment of anti-PD-1 refractory metastatic melanoma.The stock surged up 29.03% to $1.60 in after-hours trading.Organovo Terminates Merger With Tarveda Organovo Holdings Inc (NASDAQ: ONVO), a developer of 3-D bioprinted tissues comprising human cells, said it has terminated the merger agreement with Tarveda Therapeutics, which was originally announced Dec. 16. The decision follows Organova's shareholders rejecting the merger at a special meeting of stockholders.The shareholders, meanwhile, approved the proposal to effect a reverse stock split of one share for every 20 to 40 shares of existing common stock.The stock slipped 3.30% to 28 cents in after-hours trading.MediciNova to Initiate Clinical Trial of Investigational Asset MN-166 For COVID-19-induced Respiratory Distress MediciNova, Inc. (NASDAQ: MNOV) said it will initiate a clinical trial of MN-166 for acute respiratory distress syndrome caused by COVID-19."We are very pleased to announce initiation of a clinical trial of MN-166 in ARDS caused by COVID-19. This study also will allow investigators to determine the optimal dose and route of administration in these very critical patients," said Yuichi Iwaki, CEO of MediciNova.Announcements On COVID-Related Impacts Myriad Genetics, Inc. (NASDAQ: MYGN) announced withdrawal of its 2020 financial guidance, citing the impact of the COVID-19 pandemic."....recent social distancing guidelines have had a significant impact on test volume trends in late March and into the fiscal fourth-quarter," said Bryan Riggsbee, interim president and CEO and chief financial officer at Myriad Genetics.Trillium Therapeutics Inc (NASDAQ: TRIL) said it expects a slowdown or potentially a pause in new patient enrolment in its TTI-621 and TTI-622 dose escalation studies. The company, however, said its strong financial position, with about $135 million in cash and investments, will enable it to tide through the crisis and also execute on its key strategic objectives.On The Radar IPO Keros Therapeutics, which develops therapies for hematological and neuromuscular disorders, said it has priced its upsized initial public offering, or IPO, of 6 million at $16 compared to the estimated range of $14-$16. The company's shares will begin trading on the Nasdaq under the ticker symbol KROS.See more from Benzinga * The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation * The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations * The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

As of late, it has definitely been a great time to be an investor in Organovo.

Bet on these top-ranked stocks with rising P/E for outsized gains.